At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
Blood Draw +1 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis
In Brief
An observational study evaluating Blood Draw and Lumbar Puncture for Multiple Sclerosis, Relapsing-Remitting. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting
CountriesUnited States
CollaboratorsMicrostein, LLC
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartSep 2013
Primary CompletionOct 2023
TodayJul 2026
First PostedJul 26, 2013
Enrollment StartSep 20, 2013
Primary CompletionOct 5, 2023
TodayJul 2, 2026
Enrollment to primary: 10.0 yearsPosted 12.9 years ago
Interventions
Blood Drawprocedure
Patients will provide a serum sample for research.
Lumbar Punctureprocedure
Patients will have a lumbar puncture to obtain CSF.